Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Open accessThe DOI matches its Crossref record; 339 of the 341 references it cites were found in a registry or an index.
Abstract
Background: Pharmacological augmentation is a recommended strategy for patients with treatment-resistant depression. A range of guidelines provide advice on treatment selection, prescription, monitoring and discontinuation, but variation in the content and quality of guidelines may limit the provision of objective, evidence-based care. This is of importance given the side effect burden and poorer long-term outcomes associated with polypharmacy and treatment-resistant depression. This review provides a definitive overview of pharmacological augmentation recommendations by assessing the quality of guidelines for depression and comparing the recommendations made. Methods: A systematic literature search identified current treatment guidelines for depression published in English. Guidelines were quality assessed using the Appraisal of Guidelines for Research and Evaluation II tool. Data relating to the prescription of pharmacological augmenters were extracted from those developed with sufficient rigor, and the included recommendations compared. Results: Total of 1696 records were identified, 19 guidelines were assessed for quality, and 10 were included. Guidelines differed in their quality, the stage at which augmentation was recommended, the agents included, and the evidence base cited. Lithium and atypical antipsychotics were recommended by all 10, though the specific advice was not consistent. Of the 15 augmenters identified, no others were universally recommended. Conclusions: This review provides a comprehensive overview of current pharmacological augmentation recommendations for major depression and will support clinicians in selecting appropriate treatment guidance. Although some variation can be accounted for by date of guideline publication, and limited evidence from clinical trials, there is a clear need for greater consistency across guidelines to ensure patients receive consistent evidence-based care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Clinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081
Research works printed but not linked: 12
- Agid, 2006, The “delayed onset” of antipsychotic action–an idea whose time has come and gone, J Psychiatry Neurosci, 31, 93
- DeBattista, 2003, Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study, J Clin Psychiatry, 64, 1057, 10.4088/JCP.v64n0911 · DOI · Paper page
- FDA, 2019, February 12, 2019: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee - 02/12/2019 - 02/12/2019
- Fond, 2014, Ketamine administration in depressive disorders: a systematic review and meta-analysis, Psychopharmacology (Berl), 231, 3663, 10.1007/s00213-014-3664-5 · DOI · Paper page
- Hurley, 2002, Lamotrigine update and its use in mood disorders, Ann Pharmacother, 36, 860, 10.1345/aph.1A102 · doi:10.1345/aph.1a102 · Paper page
- Jensen, 1992, Combining nortriptyline and lithium in elderly depressed patients: a double-blind, placebo-controlled study, Lithium, 3, 259
- National Institute for Health and Clinical Excellence (NICE), 2009, The treatment and management of depression in adults (Updated Edition)
- Schindler, 2007, Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study, Int Clin Psychopharmacol, 22, 179, 10.1097/YIC.0b013e328014823d · DOI · Paper page
- Serafini, 2014, The role of ketamine in treatment-resistant depression: a systematic review, Curr Neuropharmacol, 12, 444, 10.2174/1570159X12666140619204251 · DOI · Paper page
- Suehs, 2008, Texas medication algorithm project procedural manual: major depressive disorder algorithms. Austin, TX: The Texas Department of State Health Services
- Taylor, 2015, The Maudsley prescribing guidelines in psychiatry
- Trivedi, 2006, Medication augmentation after the failure of SSRIs for depression, N Engl J Med, 354, 1243, 10.1056/NEJMoa052964 · DOI · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“Moreover, guidelines on how to treat TRD/PRD, such as pharmacological augmentation, are not consistent [14], and evidence on effectiveness is sparse [15].”
BackgroundSelf-citationMalhi, G. S., Bell, E., Singh, A., Bassett, D. L., Berk, M., Boyce, P. M., Bryant, R. A., Gitlin, M. J., Hamilton, A., Hazell, P., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.13035 · Cited by 131
Self-citationScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
“The exception to this rule was buspirone, for which the ES and 95% CIs were considerably higher when TRD was defined as 2 FTs (1 FT = ES = 0.84, 95% CI: 0.61–1.07; 2 FTs = ES = 1.57, 95% CI: 1.14–2.02), although this consisted of only one small study.”
BackgroundResultInfluentialSelf-citationLevkovich, I., & Elyoseph, Z. (2023) · Family Medicine and Community Health · doi:10.1136/fmch-2023-002391 · Cited by 83
“Scrutiny and handling of gender or socioeconomic biases.”
Background
Metadata
- Authors
- Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J.
- Affiliations
- King's College London (GB)
- The Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, London, United Kingdom
- Oxford Health NHS Foundation Trust (GB)
- University of Geneva (CH)
- Corresponding author
- Marwood, Lindsey
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-13
- Volume
- 23
- Issue
- 9
- Pages
- 587-625
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7710919
- OpenAlex
- W3024119889
- Cited by
- 76
- References
- 341
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 16 · 2023: 17 · 2022: 9 · 2021: 15 · 2020: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute for Health Research
- South London and Maudsley NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- drug augmentation, treatment-resistant depression, major depressive disorder, guideline quality, lithium, atypical antipsychotics, polypharmacy, evidence-based care, guideline recommendations
- MeSH terms
- Major Depressive Disorder, Drug Synergism, Drug Therapy, Combination, Humans, Drug Prescriptions, Antipsychotic Agents, Practice Guidelines as Topic, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. https://app.cochat.ai/papers/10.1093/ijnp/pyaa033
- The paper
- Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020). Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaa033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
